Dysmenorrhea Treatment Market Overview:
According to a recent study by Market Research Community, the therapies for dysmenorrhea treatment market is predicted to grow from USD XX billion in 2021 to USD XX billion in 2030.
Cramping during a period causes excruciating agony that radiates from the lower abdomen to the back, this, and the legs. About five years following the start of their menstrual cycle, many women start experiencing dysmenorrhea—agonizing pain—during the first few years of adolescence. Dysmenorrhea treatment is the name of the therapy utilised to address the issue.
North America, Europe, Asia-Pacific, and Latin America are the four regions into which the market is divided. Over the forecast period of 2022–2030, the market for treatments for dysmenorrhea is anticipated to grow significantly, with a CAGR of about 8.3%. This is despite a significant decline in product sales during the initial stages of pandemic spread and the implementation of lockdown regulations across the globe.
The report includes a regional analysis and country analysis with the latest trends, along with the major key players including Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson Johnson, and Alvogen.
The global prevalence of disorders such as endometriosis, the primary cause of secondary dysmenorrhea, is increasing. Endometriosis affects an estimated 1 in 10 women throughout their fertile years, or around 176 million people globally, according to an article titled "Understanding Endometriosis—the Basics" published in July 2021. This element is predicted to have a substantial influence on market growth. As a result of the aforementioned factors, the nonsteroidal anti-inflammatory medicine category is predicted to considerably contribute to market expansion.
North America is dominate the growth of the dysmenorrhea treatment market owing to the introduction of innovative products for treating the discomfort associated with primary and secondary dysmenorrhea. For example, in 2021, Pfizer Inc. and Myovant Sciences received FDA authorization for the assessment of a supplementary Novel Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) to treat mild to severe endometriosis pain. As a result of these reasons, the market for dysmenorrhea therapy in the United States is predicted to increase considerably over the forthcoming years.
The study is consolidated into major segments and further into sub-segments, such as by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), by Treatment Type (Non-steroidal Anti-inflammatory Drugs (NSAIDs), HormonalTherapy)to forecast the size by dysmenorrhea treatment market value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.
Contact us:
Market Research Community
